We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04819347
Recruitment Status : Not yet recruiting
First Posted : March 26, 2021
Last Update Posted : March 26, 2021
Sponsor:
Information provided by (Responsible Party):
Frontier Biotechnologies Inc.

Brief Summary:
This is a phase 2 study to evaluate the safety and tolerability of combination therapy with Albuvirtide (ABT) and 3BNC117 in virologically suppressed subjects with HIV-1 infection and explore the potential of viral suppression and viral reservoir clearance after analytical treatment interruption (ATI).

Condition or disease Intervention/treatment Phase
HIV/AIDS Drug: Albuvirtide Drug: 3BNC117 Phase 2

Detailed Description:

This is an open-label, one site study, in which a total of 24 HIV-1 subjects who are virologically suppressed and stable on daily oral combination antiretroviral therapy will be enrolled.

All eligible patients will be switched from daily oral combination antiretroviral regimen to treatment of ABT and 3BNC117 for 14 weeks. There is a two-week overlap of the baseline oral antiretroviral therapy and the ABT-3BNC117 combination regimen at the beginning of the study treatment, and then the oral ART will be interrupted.

The patients will be monitored for viral rebound every two or four weeks following initiation of ABT-3BNC117 combination and will re-initiate an oral antiretroviral regimen if virological rebound is confirmed with plasma HIV-1 RNA levels above 200 copies/ml on two consecutive test.

Pharmacokinetics of ABT and 3BNC117 will be assessed in this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Phase 2, Two Arms, One Site, Safety and Antiviral Activity of Combination Therapy With Albuvirtide and 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection After Analytical Treatment Interruption
Estimated Study Start Date : May 1, 2021
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : December 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Experimental: Early treatment of infection

HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.

Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks.

Drug: Albuvirtide
Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
Other Name: ABT

Drug: 3BNC117
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.

Experimental: Chronic period of infection treatment

Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), and had plasma HIV-1 RNA <50 copies/mL for at least 12 months.

Albuvirtide 0.32 g and 3BNC117 2 g every 2 weeks IV infusion for a total of 14 weeks.

Drug: Albuvirtide
Long-Acting HIV-1 Fusion Inhibitor (chemically modified peptide targeting HIV-1 gp41)
Other Name: ABT

Drug: 3BNC117
Recombinant, fully human mAb of the IgG1κ isotype that specifically binds to HIV-1 gp120.




Primary Outcome Measures :
  1. Proportion of participants (with sustained viral suppression at week 14) with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI) [ Time Frame: Week 26 ]
    Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26.


Secondary Outcome Measures :
  1. Mean time to virologic rebound (HIV-1 RNA≥200 copies/mL) after ATI [ Time Frame: up to 48 weeks ]
    Mean time to virologic rebound

  2. Proportion of participants without experiencing virologic rebound (HIV-1 RNA<200 copies/mL) at Week 26 (24 weeks after ATI). [ Time Frame: Week 26 ]
    Proportion of participants without experiencing virologic rebound

  3. Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26 (24 weeks after ATI). [ Time Frame: Week 26 ]
    Proportion of participants with HIV-1 RNA < 50 copies/mL at Week 26

  4. Mean change in CD4 cell count after ATI [ Time Frame: up to 48 weeks ]
    Mean change in CD4 cell count

  5. Mean change in CD4/CD8 ration after ATI [ Time Frame: up to 48weeks ]
    Mean change in CD4/CD8 ration

  6. Frequency of emergence of new resistance mutations after virologic rebound [ Time Frame: up to 48 weeks ]
    Frequency of emergence of new resistance mutations

  7. Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound [ Time Frame: up to 48 weeks ]
    Mean time to achieving HIV-1 RNA < 50 copies/mL after experiencing virologic rebound



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and females, age ≥18 years
  2. For cohort 1: HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) within 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy within 6 months of PHI.

    For cohort 2: Chronically HIV-1 infected subjects initiated a stable combination antiretroviral therapy (ART) after 6 months of primary HIV infection (PHI), having the document evidence of initial diagnosis of HIV-1 infection and initiation of ART therapy after 6 months of PHI.

  3. Plasma HIV-1 RNA <50 copies/mL for at least 12 months prior to Screening Visit. An exception for a recorded HIV-1 RNA "blip" (e.g., transient HIV-1 RNA >50 copies/mL) can be considered.
  4. Plasma HIV-1 RNA <20 copies/mL at Screening Visit.
  5. CD4 cell count >500 cells/µL.
  6. Laboratory values at Screening of:

    1. Absolute neutrophil count (ANC) ≥0.75×10∧9/L;
    2. Hemoglobin (Hb) ≥105 g/L (male) or ≥95 g/L (female);
    3. Platelets ≥75×10∧9/L;
    4. Serum alanine transaminase (SGPT/ALT) < 2 x upper limit of normal (ULN)
    5. Serum aspartate transaminase (SGOT/AST) < 2 x ULN
    6. Bilirubin (total) <2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
    7. Creatinine ≤1.5 x ULN
  7. Clinically normal resting 12-lead ECG at Screening Visit or, if abnormal, considered not clinically significant by the Principal Investigator.
  8. Both male and female patients and their partners of childbearing potential must agree to use accepted methods of contraception.
  9. Females of childbearing potential must have a negative serum pregnancy test at Screening visit and negative urine pregnancy test prior to receiving the first dose of study drug.
  10. Subjects who have two or more potential alternative antiretroviral treatment regimens.
  11. Willing and able to participate in all aspects of the study, including use of IV medication, completion of evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written informed consent.

Exclusion Criteria:

  1. Any active infection or malignancy requiring acute therapy.
  2. Hepatitis B infection as manifest by the presence of Hepatitis B surface antigen (HBsAg).
  3. Hepatitis C infection as manifest by positive anti-HCV antibody and positive HCV RNA assay at the time of screening.
  4. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
  5. Unexplained fever or clinically significant illness within 1 week prior to the first study dose
  6. Any vaccination within 2 weeks prior to the first study dose.
  7. Subjects BMI<20 or >27 kg/m∧2 [BMI=weight/height∧2].
  8. History of Bleeding Disorder or patients on anti-coagulant therapy
  9. Participation in an experimental drug trial(s) within 30 days of the Screening Visit
  10. Any known allergy or antibodies to the study drug or excipients
  11. Treatment with any of the following:

    1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit
    2. Receipt of any fusion inhibitor and monoclonal antibody therapy of any kind in the past.
    3. Immunosuppressants within 60 days prior to the Screening Visit
    4. Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit
    5. Oral or parenteral corticosteroids within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:
    6. Subjects on inhaled, nasal, or topical steroids will not be excluded
  12. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04819347


Contacts
Layout table for location contacts
Contact: Xingxiang Xu 025-69648410 xxxu@frontierbiotech.com
Contact: Cheng Yao yaocheng@frontierbiotech.com

Locations
Layout table for location information
China
Peking Union Medical College Hospital
Beijing, China
Contact: Taisheng Li, M.D.       litsh@263.net   
Principal Investigator: Taisheng Li, M.D.         
Sponsors and Collaborators
Frontier Biotechnologies Inc.
Investigators
Layout table for investigator information
Study Director: Cheng Yao Frontier Biotechnologies Inc.
Layout table for additonal information
Responsible Party: Frontier Biotechnologies Inc.
ClinicalTrials.gov Identifier: NCT04819347    
Other Study ID Numbers: ABT-3BNC117_202
First Posted: March 26, 2021    Key Record Dates
Last Update Posted: March 26, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infections
Acquired Immunodeficiency Syndrome
HIV Infections
Blood-Borne Infections
Communicable Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases